DDInter224 DDInter782
Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Bosutinib {u} (Compound) resembles {v} (Compound) Gefitinib
Bosutinib {u} (Compound) binds {v} (Gene) PTK2
Bosutinib {u} (Compound) upregulates {v} (Gene) HSD17B7
Bosutinib {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Bosutinib {u} (Compound) downregulates {v} (Gene) COTL1
Bosutinib {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Bosutinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Famotidine
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium carbonate
Bosutinib {u} may lead to a major life threatening interaction when taken with {v} Mumps virus strain B level jeryl lynn live antigen
Bosutinib (Compound) resembles Gefitinib (Compound)
Bosutinib (Compound) binds PTK2 (Gene)
Bosutinib (Compound) upregulates HSD17B7 (Gene)
Bosutinib (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Bosutinib (Compound) downregulates COTL1 (Gene)
Bosutinib (Compound) causes Cardiac disorder (Side Effect)
Bosutinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Famotidine
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Bosutinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen